ArticleBreast cancer research and treatment2014

Duration of tamoxifen use and the risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers.

Jacek Gronwald et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.